Search

everythinglearnresearchcommunity

for

Search:↓

ALRN-6924 can protect hair follicles from chemotherapy damage by temporarily stopping cell division.

Upadacitinib may effectively treat alopecia areata without side effects.

Baricitinib is effective and safe for treating severe alopecia areata with ongoing use.

The combination of mitoxantrone, etoposide, and prednisolone is effective for treating relapsed lymphoma with manageable side effects.

New pyrazole-based inhibitors show promise for treating metabolic diseases and other conditions.

Tofacitinib helped psoriasis but not alopecia universalis, needing more research.

Over 30 potential cancer prevention treatments are being tested, with some showing promise in early research.

Bicalutamide effectively treats prostate cancer but needs careful monitoring for side effects.

Ritlecitinib is a new treatment for severe hair loss in people 12 and older.

Tofacitinib helped a 19-year-old regrow hair after other treatments failed.

Vitexin Compound 1 may help reduce skin aging caused by UVA light.

Atorvastatin reversed memory problems caused by cancer drug trastuzumab and improved its cancer-fighting abilities without causing hair loss.

JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.

The nature of the side chain in RU 58841 derivatives greatly affects its AR affinity, with the N-(iodopropenyl) derivative 13 showing the highest AR binding affinity, suggesting its potential for developing high-affinity radioiodinated AR radioligands.

WYE-130600 may cause skin thickening and irritation.

A man developed skin issues from cancer medication, which improved with specific treatments.

Janus kinase inhibitors help some people with severe alopecia areata regrow hair, but not everyone responds, and relapses can happen.

Baricitinib improved hair loss and arthritis in a lupus patient.

Baricitinib treatment helped reduce hair loss symptoms in mice by decreasing inflammation-related immune cells.

PROTACs show promise for cancer treatment, but designing them effectively is challenging.

Ablative fractional laser treatment nearly matches the gene reduction effects of topical vismodegib in skin cancer.

Using 5-alpha-reductase inhibitors may improve bladder cancer survival in men.

Combining Ficlatuzumab and Gefitinib can cause severe hair loss.

Tribuloside can increase skin pigmentation by enhancing melanin production and distribution.

MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.

Vismodegib is effective for basal cell carcinoma but has severe side effects.

Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.